Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.